Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV
巨细胞病毒 (CMV)、HIV 的肠道屏障和免疫功能障碍
基本信息
- 批准号:10578682
- 负责人:
- 金额:$ 77.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-15 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AIDS clinical trial groupAcquired Immunodeficiency SyndromeAddressAncillary StudyAntigen PresentationBiological MarkersCD8-Positive T-LymphocytesCellsChronicClinical TrialsColorectalCytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesDNADefectDendritic CellsDiseaseEpitopesFailureFunctional disorderFundingGastrointestinal tract structureGeneral PopulationGut MucosaHIVHIV InfectionsHomingImmune System DiseasesIndividualInfectionLife ExpectancyMacaca mulattaMeasuresMediatingModelingModified Vaccinia Virus AnkaraMucous MembraneParentsParticipantPathogenesisPathway interactionsPersonsPharmaceutical PreparationsPlasmaPrediction of Response to TherapyRecording of previous eventsRoleSeriesSiteSpecificityT cell responseT-Cell ActivationT-LymphocyteTestingTherapeuticTight JunctionsTissuesTretinoinUnited States National Institutes of HealthVaccinationVaccine TherapyVaccinesantigen-specific T cellsantiretroviral therapybaseco-infectioncohortexhaustiongastrointestinalgastrointestinal epitheliumimmune activationimprintimprovedimproved outcomein vivointestinal barriermicrobialmortalityperipheral bloodresponsesenescencetraffickingvaccination strategyvaccine strategyvector vaccine
项目摘要
ABSTRACT. This REVISED collaborative R01 application addresses the impact of cytomegalovirus (CMV) on
the gastrointestinal mucosa in chronic HIV infection. We hypothesize that CMV infection contributes to the
intestinal barrier dysfunction and consequent immune activation that persist in chronic HIV infection despite
suppressive antiretroviral therapy (ART). In Aim 1, based on strong preliminary studies, we hypothesize that
CMV persistence in the gastrointestinal tract results in part from the failure of CMV-specific CD8+ T-cells to
localize to this tissue. To determine the breadth and functionality of CMV-specific T-cell responses in gut, we will
measure responses in colorectal tissue from participants in the SCOPE cohort at UCSF. To determine the effects
of CMV infection on antigen presentation in gut, we will employ the rhesus macaque model of CMV (RhCMV)
and SIVmac to study interactions between mucosal dendritic cells (DC) and T-cells ex vivo. In Aim 2, we will
leverage an externally-funded clinical trial (AIDS Clinical Trials Group Study #A5383) to directly test the
hypothesis that asymptomatic CMV replication contributes significantly to microbial translocation in treated HIV
disease. We will determine the effects of suppression of CMV replication with letermovir on systemic biomarkers
of microbial translocation as well as immune activation and gut barrier integrity assessed directly in gut mucosal
tissues. Taken together, these studies will determine the contributions of CMV to immune activation in HIV
disease, and the mechanistic bases for these effects. Aim 3 leverages a second ACTG study (#A5355) to
determine whether a modified vaccine Ankara (MVA)-based CMV vaccine can increase systemic and/or gut-
homing and mucosal CMV-specific T-cell responses in treated HIV infection. Failure of a therapeutic anti-CMV
vaccine to elicit gut-homing CMV-specific T-cell responses and to reduce mucosal CMV shedding may
compromise its ability to reduce systemic immune activation in treated HIV infection and would highlight the need
for optimization of vaccination strategies to improve mucosal responses. (Note: Aims 2 and 3 do not meet the
NIH definition of a clinical trial; the ancillary studies in these Aims only add additional measures to pre-existing
trials).
摘要。本修订版协作R 01应用程序解决了巨细胞病毒(CMV)对
慢性HIV感染者的胃肠道粘膜。我们假设CMV感染有助于
肠屏障功能障碍和随后免疫激活在慢性HIV感染中持续存在,
抑制性抗逆转录病毒治疗(ART)。在目标1中,基于强有力的初步研究,我们假设,
CMV在胃肠道中的持续存在部分是由于CMV特异性CD 8 + T细胞未能在胃肠道中表达,
定位于这个组织。为了确定肠道中CMV特异性T细胞应答的广度和功能,我们将
测量加州大学旧金山分校SCOPE队列参与者的结直肠组织反应。以确定影响
为探讨巨细胞病毒感染对肠道抗原提呈的影响,我们采用恒河猴巨细胞病毒感染模型(RhCMV)
和SIVmac来研究离体粘膜树突状细胞(DC)和T细胞之间的相互作用。在目标2中,我们将
利用外部资助的临床试验(艾滋病临床试验组研究#A5383)直接测试
无症状CMV复制显著促进HIV治疗后微生物易位的假说
疾病我们将确定用莱特莫韦抑制CMV复制对全身性生物标志物的影响。
微生物移位以及免疫激活和肠道屏障完整性直接在肠道粘膜中评估
组织中总之,这些研究将确定CMV对HIV免疫激活的贡献
疾病,以及这些影响的机制基础。目标3利用第二项ACTG研究(#A5355),
确定基于改良疫苗安卡拉(MVA)的CMV疫苗是否可以增加全身和/或肠道-
归巢和粘膜CMV特异性T细胞反应在治疗HIV感染。治疗性抗CMV治疗失败
引起肠道归巢CMV特异性T细胞应答和减少粘膜CMV脱落的疫苗可
损害其在治疗的HIV感染中减少全身免疫激活的能力,并将突出需要
用于优化疫苗接种策略以改善粘膜反应。(Note:目标2和3不符合
NIH对临床试验的定义;这些目的中的辅助研究仅在既存研究的基础上增加额外措施
审判)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER W HUNT其他文献
PETER W HUNT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER W HUNT', 18)}}的其他基金
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection
治疗无症状 CMV 复制对 HIV 感染治疗者心血管风险的影响
- 批准号:
10715847 - 财政年份:2023
- 资助金额:
$ 77.05万 - 项目类别:
Assessing the Interrelationship Between Adipose Tissue Thermogenesis and Fibrosis in the Metabolic Health of People Living with HIV
评估艾滋病毒感染者代谢健康中脂肪组织产热与纤维化之间的相互关系
- 批准号:
10626188 - 财政年份:2022
- 资助金额:
$ 77.05万 - 项目类别:
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV
巨细胞病毒 (CMV)、HIV 的肠道屏障和免疫功能障碍
- 批准号:
10177602 - 财政年份:2021
- 资助金额:
$ 77.05万 - 项目类别:
Plasma Proteomic and Metabolomic Predictors of Vascular Disease in Treated HIV
HIV治疗者血管疾病的血浆蛋白质组学和代谢组学预测因子
- 批准号:
10331583 - 财政年份:2021
- 资助金额:
$ 77.05万 - 项目类别:
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV
巨细胞病毒 (CMV)、HIV 的肠道屏障和免疫功能障碍
- 批准号:
10875189 - 财政年份:2021
- 资助金额:
$ 77.05万 - 项目类别:
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV
巨细胞病毒 (CMV)、HIV 的肠道屏障和免疫功能障碍
- 批准号:
10372191 - 财政年份:2021
- 资助金额:
$ 77.05万 - 项目类别:
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection
治疗无症状 CMV 复制对 HIV 感染治疗者心血管风险的影响
- 批准号:
10242227 - 财政年份:2020
- 资助金额:
$ 77.05万 - 项目类别:
Persistent Functional Immune Defects in Treated HIV Infection
HIV感染治疗后持续存在功能性免疫缺陷
- 批准号:
9927206 - 财政年份:2020
- 资助金额:
$ 77.05万 - 项目类别:
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection
治疗无症状 CMV 复制对 HIV 感染治疗者心血管风险的影响
- 批准号:
10449260 - 财政年份:2020
- 资助金额:
$ 77.05万 - 项目类别:
Persistent Functional Immune Defects in Treated HIV Infection
HIV感染治疗后持续存在功能性免疫缺陷
- 批准号:
10593968 - 财政年份:2020
- 资助金额:
$ 77.05万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 77.05万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 77.05万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 77.05万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 77.05万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 77.05万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 77.05万 - 项目类别:
Studies on cofactors for development of acquired immunodeficiency syndrome in feline immunodeficiency virus infection.
猫免疫缺陷病毒感染后获得性免疫缺陷综合征发生的辅助因子研究。
- 批准号:
03660315 - 财政年份:1991
- 资助金额:
$ 77.05万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 77.05万 - 项目类别: